Skip to Content

Padmanee Sharma

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, Department of Immunology, Division of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
Regular Member, U.T. Faculty of the Graduate School of Biomedical Sciences, Houston, TX
Associate Clinical Director, Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center, New York, NY

Education & Training

Degree-Granting Education

1998 Pennsylvania State University, College of Medicine, Philadelphia, PA, MD, Medicine
1998 Pennsylvania State University, College of Medicine, Philadelphia, PA, Ph.D., Immunology
1991 Boston University, Boston, MA, MA, Biotechnology
1990 Boston University, Boston, MA, BA, Biology

Postgraduate Training

7/2000-7/2004 Clinical Fellowship, Medical Oncology, Memorial-Sloan Kettering Cancer Center, New York, NY
7/1998-7/2000 Clinical Residency, Internal Medicine, New York Hospital, Cornell Medical Center, New York, NY

Board Certifications

1/2003 Board Certified Medical Oncology
1/2000 Board Certified Internal Medicine

Experience/Service

Academic Appointments

Fellow, Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, 7/2000-7/2004
Resident, New York Hospital, Cornell Medical Center, New York, NY, 7/1998-7/2000

Other Appointments/Responsibilities

Consultant, Ipilimumab Prostate Advisory Board, New York, 2009
Consultant, Bristol-Myers Squibb Immunology Biomarker Advisory Board, Miami, 2008

Honors and Awards

2009 American Cancer Society Mentored Research Scholar Grant
2008 Doris Duke Clinical Scientist Development Award
2008 Melanoma Research Alliance Young Investigator Award
2008 Prostate Cancer Foundation Challenge Award in Immunology
2007 Carl C. Anderson, Sr. & Marie Jo Anderson Charitable Foundation
2007 M. D. Anderson Cancer Center Bladder Cancer SPORE Development Award
2007 The Gillson Longenbaugh Foundation
2006 American Society of Clinical Oncology Career Development Award
2006 Cancer Research Institute Clinical Investigator Award
2006 Prostate Cancer Foundation Young Investigator Award
2005 M. D. Anderson Cancer Center Institutional Research Grant
2005 M. D. Anderson Cancer Center Physician Scientist Training Program Award
2005 National Institute of Health Renewal Clinical Loan Repayment Program Award
2003 American Society of Clinical Oncology, Young Investigator Award Recipient
2003 Award Recipient, GSK National Medical Oncology Fellows Forum
2002 Award for Abstract Presentation, Doris Duke Symposium
2001 Memorial Sloan-Kettering Cancer Center Institutional NIH T32 Grant
1998 Scholarship for Excellence in Medicine, Pennsylvania State University, Department of Medicine
1995 Student Clinician Research Award, Pennsylvania State University
1994 The Judy S. Finkelstein Memorial Award in Immunology
1990 Golden Key National Honor Society

Professional Memberships

American Association for Cancer Research (AACR)
Member, 2006-present
American Society of Clinical Oncology (ASCO)
Member, 2005-present
Anti-CTLA Clinical Trials, LICR/CRI/BMS Initiative
Subcommittee, 2006
Bristol-Myers Squibb, Immunology Biomarker Advisory Board, Miami, FL
Ad hoc, 2006
International Society for Biological Therapy of Cancer (iSBTc)
Member, 2005-present
Ipilimumab Prostate Advisory Board, New York, NY
Ad hoc, 2008
Women in Cancer Research (AACR), Philadelphia, PA
Member, 2009-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Matin SF, Sharma P, Gill S, Tannenbaum C, Hobart M, Novick AC, Finke JH. Immunologic tesponses to renal cryoablation in an in-vivo orthotopic renal cell carcinoma murine model. Journal of Urology. In Press.
2. Chen H, Liakou CI, Kamat A, Pettaway C, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logthetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-{gamma} levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA 106:2729-34, 2009. PMID: 19202079.
3. Gnjatic S, Altorki N, Ng Tang D, Tu SM, Kundra V, Old LJ, Sharma P. NY-ESO-1DNA vaccine induces T cell responses that are suppressed by regulatory T cells. Clin Cancer Res 15:2130-9, 2009. PMID: 19276258.
4. Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 8:9, 2008. PMID: 18503261.
5. Liakou C, Kamat A, Chen H, Ng Tang D, Sun J, Troncoso P, Logothetis C., Sharma P. CTLA-4 blockade increases IFN-y-producing CD4+ICOShi T cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 105:14987-92, 2008. PMID: 18818309.
6. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunotherapy 31:849-57, 2008. PMID: 18833002.
7. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 104:19458-63, 2007. PMID: 18042703.
8. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth A, Gnjatic S, Bajorin D, Reuter V, Herr H, Old L, Sato E. CD 8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 104:3967-72, 2007. PMID: 17360461.
9. Kopetz S, Jimenez CA, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Resp J 29:813-5, 2007.
10. Sharma P, Shen Y, Wen S. Bajorin D, Reuter V, Old L, Jungbluth A. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12:5442-7, 2006. PMID: 17000678.
11. Sharma P, Gnjatic S, Jungbluth AA, Williamson B, Herr H, Stockert E, Dalbagni G, Donat SM, Reuter VE, Santiago D, Chen YT, Bajorin DF, Old LJ. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T cell epitope in a patient with bladder cancer. Cancer Immun 3:19, 2003. PMID: 14680360.
12. Sharma P, Page MJ, Poritz LS, Koltun WA, Chorney MJ. An increased gamma delta T cell population in the intestine of thymus-leukemia antigen transgenic mice. Cell Immunol 176:153-7, 1997. PMID: 9073388.
13. Joyce S, Negishi I, Boestanu A, DeSilva DA, Sharma P, Chorney MJ, Loh DY, Van Kaer L. Expansion of natural (NK1+) T cells that express alpha/beta T-cell receptors in transporters associated with antigen presentation-1 null and thymus-leukemia antigen positive mice. J Exp Med 184:1579, 1996.
14. Venditti CP, Lawlor DA, Sharma P, Chorney MJ. Structure and content of the major histocompatibility complex (MHC) class I regions of the great anthropoid apes. Human Immunology 49:71-84, 1996.
15. Sharma P, Joyce S, Chorney K, Griffith J, Bonneau RH, Wilson F, Flavell R, Chorney MJ. The thymus-leukemia antigen, T18d, interacts with T cells and self peptides. J Immunol 156:987, 1996.
16. Sharma P, Johnson CA, Bonneau RH, Lang CM, Chorney MJ. Thymus-leukemia antigen transgenic mice fail to control cutaneous herpes simplex virus infection. Cell Immunol 174:84, 1996.

Invited Articles
1. Aparicio A, Sharma P, Millikan RE. Experimental systemic therapy of metastatic urothelial cancer. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA. In Press.
2. Mittendorf, E. Sharma, P. Mechanisms of T cell inhibition: Implications for cancer immunotherapy. Expert Review of Vaccines. In Press.
3. Carthon B, Sharma P. Advanced Urothelial Carcinoma: Current Treatment Strategies and Novel Agents in Clinical Trials. CML Urology 14:57-68, 2009.
4. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in bladder cancer. Cancer Immun 7:813-15, 2007. PMID: 17591743.
5. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high risk bladder cancer. Semin Onc 34:165-72, 2007. PMID: 17382800.
6. Pagliaro LC, Sharma P. Review of metastatic bladder cancer. Minerva Urol Nefrol 58:53-71, 2006.
7. Sharma P, Donat MS, Herr H, Bajorin D. Treatment of locally advanced bladder cancer. Princ Prac Oncol Updates 16:8, 2001.

Abstracts
1. Sharma P. Immune Responses Mediated by CTLA-4 Blockade. ABCAM Immune Tolerance in Cancer and Autoimmune Disease Conference, 2009.
2. Sharma P. Immune Responses Mediated by CTLA-4 Blockade. Melanoma Research Alliance Annual Meeting, 2009.
3. Sharma P. Immunize Responses Mediated by CTLA-4 Blockade. Keystone Symposia: Mobilizing Cellular Immunity for Cancer Therapy, 2009.
4. Sharma P. Immunologic Impact of Anti CTLA-4 Therapy. American Association for Cancer Research Annual Meeting, 2009.
5. Sharma P. Immunologic Impact of Anti-CTLA-4 Therapy. American Society of Clinical Oncology Annual Meeting, 2009.
6. Sharma P. Is there Still a Role for Immunotherapy in the Treatment of Metastatic Renal Cell Carcinoma. M. D. Anderson Cancer Center - Urology Oncology Conference, 2009.
7. Sharma P. Systemic Chemotherapy for Urothelial Carcinoma. M. D. Anderson Cancer Center 9th Annual Oncology Update: Advances and Controversies, 2009.
8. Sharma P. Functional and Phenotypic Impact of Anti-CTLA-4 Antibody in the Pre-surgical Setting. American Association for Cancer Research Annual Meeting, 2008.
9. Sharma P. Immunologic Impact of Anti-CTLA-4 Therapy. Cancer Research Institute Annual Meeting, 2008.
10. Sharma P. Immunotherapy for Renal Cell Carcinoma. M. D. Anderson Cancer Center, 2008.
11. Sharma P. Immunology Impact of Anti-CTLA-4 Antibody in a Neoadjuvant Setting. Cancer Research Institute Annual Meeting, 2007.
12. Sharma P. Immunotherapy for Prostate Cancer. Prostate Cancer Foundation Annual Meeting, 2007.
13. Sharma P. Monitoring Immune Response in Patients Treated with Immunotherapy, Physician-Scientist/Clinician Investigator Update. M. D. Anderson Cancer Center Pioneers Group, 2007.
14. Sharma P. Studying Immune Responses to the NY-ESO-1 Antigen in Transitional Cell Carcinoma Patients. M. D. Anderson Cancer Center Genitourinary Medical Oncology Bladder SPORE, 2007.
15. Sharma P. CD8+ Tumor-Infiltrating Lymphocytes as a Statistically Significant Marker of Disease Recurrence and Survival in Transitional Cell Carcinoma Patients. American Society of Clinical Oncology Annual Meeting, 2006.
16. Sharma P. Regulatory T-cells Are Increased in the Tumor Microenvironment of Prostate Cancer Patients. Cancer Research Institute Annual Meeting, 2006.
17. Sharma P. Combinatorial Targeting of the NY-ESO-1 Cancer Testis Antigen. Cancer Research Institute Annual Meeting, 2005.
18. Sharma P. Protein and DNA-based Vaccines With NY-ESO-1 Antigen in Cancer Patients. International Society for Biological Therapy of Cancer Annual Meeting, 2005.
19. Sharma P. Protein and DNA-based Vaccines with the NY-ESO-1 Antigen in Cancer Patients. National Cancer Institute Center of Excellence in Immunology, 2005.

Book Chapters
1. Peggs KS, Quezada SA, Sharma P, Allison JP. Cancer Immunotherapy. In: Cancer Medicine 9th Edition, 2009.

Grant & Contract Support

Title: CTLA-4 Blockade in Therapy of Prostate Cancer
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 7/1/2009 - 6/30/2011
 
Title: Defining the Role of ICOS-expressing T Cells Against Melanoma
Funding Source: Melanoma Research Alliance Young Investigators Award
Role: Principal Investigator
Duration: 9/2008 - 10/2010
 
Title: Enhancing Immune Responses Against Bladder Cancer
Funding Source: Carl C. Anderson Sr. & Marie Jo Anderson Charitable Foundation
Role: Principal Investigator
Duration: 9/2008 - 8/2009
 
Title: Blockade of CTLA-4 to Induce Effective Anti-tumor Immune Responses in Cancer Patients
Funding Source: Doris Duke Charitable Foundation
Role: Principal Investigator
Duration: 8/1/2008 - 7/31/2011
 
Title: CTLA-4 Blockade in Therapy of Prostate Cancer: Therapeutic Mechanisms and New Directions
Funding Source: PCF Challenge Award
Role: Co-Investigator
Duration: 7/1/2008 - 6/30/2011
 
Title: Characterizing Immunological Responses for Correlation with Clinical Outcome in Prostate Cancer Patients Treated with Anti-CTLA-4 Therapy in the Neoadjuvant Setting
Funding Source: Prostate Cancer Foundation Young Investigator Award
Role: Principal Investigator
Duration: 10/10/2007 - 11/14/2009
 
Title: Enhancing Immune Responses Against Bladder Cancer
Funding Source: The Gillson Longenbaugh Foundation
Role: Principal Investigator
Duration: 9/1/2007 - 8/31/2009
 
Title: Enhancing Immune Responses Against Bladder Cancer
Funding Source: Carl C. Anderson Sr. & Marie Jo Anderson Charitable Foundation
Role: Principal Investigator
Duration: 9/2007 - 8/2008
 
Title: Enhancing Immune Responses Against Bladder Cancer
Funding Source: The Gillson Longenbaugh Foundation
Role: Principal Investigator
Duration: 8/2007 - 8/2008
 
Title: Determining Regulatory T-Cell Influences on Effector T-Cell Function in Prostate Cancer Patients
Funding Source: UTMDADCC Institutional Research Grant
Role: Principal Investigator
Duration: 1/26/2007 - 1/26/2008
 
Title: Identification and Correlation of Immune Responses and Tumor Responses in Transitional Cell Carcinoma Patients Treated with Immunotherapy Agents
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/2006 - 6/2009
 
Title: Effector and Regulatory T cell Responses in Prostate Cancer Patients
Funding Source: Cancer Research Institute Clinical Investigator Grant
Role: Principal Investigator
Duration: 2/1/2006 - 9/30/2010
 
Title: Identification and Correlation of Immune Responses and Tumor Responses in Transitional Cell Carcinoma Patients Treated with NY-ESO-1 Vaccine
Funding Source: UTMDACC Physician Scientist Training Program Award
Role: Principal Investigator
Duration: 9/2005 - 9/2009
 
Title: Studying Immune Responses to the NY-ESO-1 Antigen in Transitional Cell Carcinoma
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 9/2005 - 8/2006
 
Title: Targeting NY-ESO-1 and Other Novel Tumor Antigens for Cancer Immunity
Funding Source: UTMDACC Shooting Down Cancer Institutional Research Grant
Role: Principal Investigator
Duration: 8/23/2005 - 8/23/2006

Last updated: 11/10/2009